| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2426 |
| Trial ID | NCT04512716 |
| Disease | Diffuse Large B-Cell Lymphoma | B-Cell Acute Lymphoblastic Leukemia | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Non-Hodgkin's Lymphoma | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma |
| Year | 2020 |
| Country | United States |
| Company sponsor | Memorial Sloan Kettering Cancer Center |
| Other ID(s) | 20-382 |
| Cohort 1 | |||||||||
|
|||||||||